Drug Treatment of Peripheral Vascular Disease

Heart Disease

Volumn 2, Issue 1, 2000, Pages 62-74

  Eberhardt, Robert T ^a,b   Coffman, Jay D ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; RAYNAUD PHENOMENON; REVIEW; VEIN THROMBOSIS;

ARTERIOSCLEROSIS OBLITERANS; HUMAN; PERIPHERAL VASCULAR DISEASES; RAYNAUD'S DISEASE; VENOUS THROMBOSIS;

EID: 0033756729     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159:337-345.
2. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med 1990;113:135-146.
3. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J 1996;155:1053-1059.
4. Lindgarde F, Jelnes R, Bjorkman H, Adielsson G, Kjellstrom T, Palmquist I, et al, for the Scandinavian Study Group. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 1989;80:1549-1556.
5. Stergachis A, Sheingold S, Luce BR, Psaty RM, Revicki DA. Medical care and cost outcomes after pentoxifylline treatment for peripheral arterial disease. Arch Intern Med 1992;152:1220-1224.
6. Gillings DB. Pentoxifylline and intermittent claudication: review of clinical trials and cost effectiveness analyses. J Cardiovasc Pharmacol 1995;25(suppl 2):S44-S50.
7. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998;18: 1942-1947.
8. Ishizaka N, Taguchi J, Kimura Y, Ikari Y, Aizawa T, Togo M, et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 1999;142:41-46.
9. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-274.
10. Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-686.
11. Strandness DE, Dalman R, Panian S, Rendell M, Comp P, Bortey EB, et al. Two doses of cilostazol versus placebo in the treatment of claudication: results of a randomized, multicenter trial. Circulation 1998;98:I-12
12. Hiatt WR. Medical treatment of claudication. IV. Morbidity of PAD: medical approaches to claudication. In, Hirsh AT, Hiatt WR (eds.): An Office-based Approach to the Diagnosis and Treatment of Peripheral Arterial Disease. Continuing education monograph series from the American Journal of Medicine. Bellemead, NJ: Excerpta Medica, 1999;6-15.
13. Goldhaber SZ, Manson JE, Stampfer MJ, LaMotte F, Rosner B, Buring JE, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992;340:143-145.
14. Libretti A, Catalano M. Treatment of claudication with dipyridamole and aspirin. Int J Clin Pharm Res 1986;6:59-60.
15. Giansante G, Calabrese S, Fisicaro M, Fiotti N, Mitri E. Treatment of intermittent claudication with antiplatelet agents. J Int Med Res 1990;18:400-407.
16. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind artenographically controlled trial. Lancet 1985;1:415-419.
17. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med 1989;114:84-91.
18. Arean JC, Panak E. Ticlopidine in the treatment of peripheral occlusive arterial disease. Semin Thromb Hemost 1989;15:167-170.
19. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, et al. for the Swedish Ticlopidine Multicentre Study (STIMS). Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine. J Intern Med 1990;227:301-308.
20. The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAP RIE) Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996;348:1329-1339.
21. Brevetti G, Angelini C, Rosa M, Carrozzo R, Perna S, Corsi M, et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991;84:1490-1495.
22. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992;73:346-353.
23. Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. Propionyl-L car nitine in intermittent claudication: double blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995;26:1411-1416.
24. Brevetti G, Perna S, Sabba C, Martone VD, Di Iorio A, Barletta G. Effect of propionyl-L-carnitine on quality of life in intermittent claudication. Am J Cardiol 1997;79:777-780.
25. The ICAI study group. Prostanoids for chronic critical leg ischemia: a randomized, controlled, open-label trial with prostaglandin E1. Ann Intern Med 1999; 130:412-421.
26. Belch JJ, Bell PR, Creissen D, Dormandy JA, Rester RG, McCollum RD, et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997;95:2298-2302.
27. Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease: the additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 1994;90:818-822.
28. Coffman JD. Drug therapy: vasodilator drugs in peripheral vascular disease. N Engl J Med 1979;300:713-717.
29. Bagger JP, Helligsoe P, Randsbaek F, Kimose HH, Jensen BS. Effect of verapamil in intermittent claudication: a randomized, double-blind, placebo-con trolled, cross-over study after individual dose-response assessment. Circulation 1997;95:411-414.
30. Schellong SM, Roger RH, Burchert W, Bode-Boger SM, Galland A, Frolich, et al. Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: a H215O positron emission tomography study. Clin Sci 1997;93:159-165.
31. Boger RH, Bode-Boger SM, Thiele W, Greutzig A, Alexander K, Frolich, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32:1336-1344.
32. Maxwell AJ, Anderson B. Improvment in walking distance and quality of life in peripheral arterial disease by a nutritional product designed to enhance nitric oxide activity. J Am Coll Cardiol 1999;33:277A.
33. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996;94:3281-3290.
34. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-1123.
35. Hamilton M, Wilson GM, Armitage P, Boyd JT. The treatment of intermittent claudication with vitamin E. Lancet 1953;1:367-370.
36. Livingstone PD, Jones C. Treatment of intermittent claudication with vitamin E. Lancet 1958;2:602-604.
37. Tornwall M, Virtamo J, Haukka JK, Aro A, Albanes D, Edwards BK, et al. Effect of alpha-tocopherol (vitamin E) and beta-carotene supplementation on the incidence of intermittent claudication in male smokers. Arterioscler Thromb Vasc Biol 1997;17:3475-3480.
38. Ouriel K, Veith FJ, Sasahara AA, for the Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998;338:1105-1111.
39. Berridge DC, Gregson RH, Hopkinson RR, Makin GS. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolyis. Br J Surg 1991;78:988-995.
40. Lonsdale RJ, Herridge DC, Earnshaw JJ, Harrison JD, Gregson RH, Wenham PW, et al. Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis. Br J Surg 1992;79:272-275.
41. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion: a consensus document. Am J Cardiol 1998;81:207-218.
42. De Cree J, Leempoels J, Geukens H, Verhaegen H. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication. Lancet 1984;2:775-779.
43. Thulesius O, Lundvall J, Kroese A, Stranden E, Hallbook T, Brunes L, et al. Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications. J Cardiovasc Pharmacol 1987;9:728-733.
44. Clement DL, Duprez D. Effect of ketanserin in the treatment of patients with intermittent claudication: results from 13 placebo-controlled parallel group studies. J Cardiovasc Pharmacol 1987;10(suppl 3):S89-S95.
45. Prevetion of Atherosclerotic Complications with Ketanserin Trial Group. Prevention of atherosclerotic complications: controlled trial of ketanserin. Br Med J 1989;298:424-430.
46. Moody AP, al-Khaffaf HS, Lehert P, Harris PL, Charlesworth D. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994;23(suppl 3):S44-S47.
47. Strano A, Farced J, Sabba C, Albano O, Allegra C, Carlizza A, et al. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease. Semin Thromb Hemost 1991;17 Suppl 2:228-234.
48. Sabba C, Zupo V, Dina F, Nazzari M, Albano O. A pilot evaluation of the effect of defibrotide in patients affected by peripheral arterial occlusive disease. Int J Clin Pharm Ther Toxi 1988;26:249-252.
49. Trubestein G, Balzer K, Bisler H, Kluken N, Muller-Wiefel H, Unkel B, et al. Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology 1984;35:500-505.
50. Pignoli P, Ciccolo F, Villa V, Longo T. Comparative evaluation of bluflomedil and pentoxifylline in patients with peripheral arterial occlusive disease. Curr Ther Res 1985;37:596-606.
51. Chacon-Quevedo A, Eguaras MG, Calleja F, Garcia MA, Roman M, Casares, et al. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs. Angiology 1994; 45:647-653.
52. Kiesewetter H, Blume J, Jung F, Spitzer S, Wenzel E. Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb. J Intern Med 1990;227:107-114.
53. Ernst E, Kollar L, Matrai A. A double-blind trial of dextran-haemodilution vs. placebo in claudicants. J Intern Med 1990;227:19-24.
54. Sloth-Nielsen J, Guldager B, Mouritzen C, Lund EB, Egeblad M, Norregaard O, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg 1991;162:122-125.
55. Guldager B, Jelnes R, Jorgensen SJ, Nielsen JS, Klaerke A, Mogensen, et al. EDTA treatment of intermittent claudication: a double-blind, placebo-controlled study. J Intern Med 1992;231:261-267.
56. Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983;308:880-883.
57. Creager MA, Pariser KM, Winston EM, Rasmussen HM, Miller KB, Coffman, et al. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon. Am Heart J 1984;108:370-373.
58. Costantini A, Martelli E, Bavera P, Agus GB. Slow release nifedipine in the treatment of Raynaud's phenomenon. Int Angiol 1987;6:359-363.
59. La Civita L, Pitaro N, Rossi M, Gambini I, Giuggioli D, Cini G, et al. Amlodipine in the treatment of Raynaud's phenomenon. Br J Rheumotol 1993;32: 524-525.
60. Kallenberg CG, Wouda AA, Meems L, Wesseling H. Once daily felodipine in patients with primary Raynaud's phenomenon. Eu J Clin Pharmacol 1991;40: 313-315.
61. Schmidt JF, Valentin N, Nielsen SL. The clinical effect of felodipine and nifedipine in Raynaud's phenomenon. Eu J Clin Pharmacol 1989;37:191-192.
62. Leppert J, Jonasson T, Nilsson H, Ringqvist I. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study. Cardiovasc Drug Ther 1989;3:397-401.
63. French Cooperative Multicenter Group for Raynaud's Phenomenon. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. Am Heart J 1991;122:352-355.
64. Gjorup T, Hartling OJ, Kelbaek H, Nielsen SL. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. Eu J Clin Pharmacol 1986;31:387-389.
65. Kahan A, Amor B, Menkes CJ. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 1985;44:30-33.
66. Da Costa JT, Gomes JAM, Santo JE, Queiros MV. Inefficacy of diltiazem in the treatment of raynaud's phenomenom with asociated connective tissue disease: a double blind placebo controlled study. J Rheumatol 1987;14:858-859.
67. Kinney EL, Nicholas GG, Gallo J, Pontoriero C, Zelis R. The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol 1982;22:74-76.
68. Wollersheim H, Thien T, Fennis I, van Elteren P, van't Laar A. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. Clin Pharmocol Ther 1986;40:219-225.
69. Russell IJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study. J Rheumatol 1985;12:94-98.
70. Nielsen SL, Vitting K, Rasmussen K. Prazosin treatment of primary Raynaud's phenomenon. Eu J Clin Pharmacol 1983;24:421-423.
71. Aylward M, Bater PA, Davies DE, Dewland PM, Lewis PA, Maddock J. Long-term monitoring of the effects of thymoxamine hydrochloride tablets in the management of patients with Raynaud's disease. Curr Med Res Opin 1982;8: 158-170.
72. Coffman JD, Cohen AS. Total and capillary fingertip blood flow in Raynaud's phenomenon. N Engl J Med 1971;285:259-263.
73. McFadyen IJ, Housley E, MacPherson AI. Intraarterial reserpine administration in Raynaud syndrome. Arch Intern Med 1973;132:526-528.
74. Clifford PC, Martin MF, Sheddon EJ, Kirby JD, Baird RN, Dieppe PA. Treatment of vasospastic disease with prostaglandin E1. Br Med J 1980;281:1031-1034.
75. Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome. Ann Rheum Dis 1985;44:754-760.
76. Belch IJ, McKay A, McArdle B, Leiberman P, Pollock JG, Lowe GD, et al. Epoprostenol (prostacyclin) and severe arterial disease: a double-blind trial. Lancet 1983;1:315-317.
77. Dowd PM, Martin MF, Cooke ED, Bowcock SA, Jones R, Dieppe PA, et al. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol 1982;106:81-89.
78. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
79. Rademaker M, Cooke FD, Almond NE, Beacham JA, Smith RE, Mant TG, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. Br Med J 1989;298:561-564.
80. Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998;41:670-677.
81. Belch JJ, Capell HA, Cooke ED, Kirby JD, Lau CS, Madhok R, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 1995;54:197-200.
82. Coffman JD, Clement DL, Creager MA, Dormandy JA, Janssens MM, McKendry RJ, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989;87:264-268.
83. Lopez-Ovejero JA, Saal SD, D'Angelo WA, Cheigh JS, Stenzel KH, Laragh, et al. Reversal of vascular and renal crises of scleroderina by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979;300:1417-1419.
84. Tosi S, Marchesoni A, Messina K, Bellintani C, Sironi G, Faravelli C. Treatment of Raynaud's phenomenon with captopril. Drugs Exp Clin Res 1987;13: 37-42.
85. Pancera P, Sansone S, Secchi S, Covi G, Lechi A. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon. J Intern Med 1997;242:373-376.
86. Franks AG. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet 1982;1:76-77.
87. Neirotti M, Longo F, Molaschi M, Macchione C, Pernigotti L. Functional vascular disorders: treatment with pentoxifylline. Angiology 1987;38: 575-580.
88. Peacock JH. The treatment of primary Raynaud's disease of the upper limb. Lancet 1960;2:65-69.
89. Dessein PH, Morrison RC, Lamparelli RD, van der Merwe CA. Triiodothyronine treatment for Raynaud's phenomenon: a controlled trial. J Rheumatol 1990;17:1025-1028.
90. Belch JJ, Cormie J, Newman P, McLaren M, Barbenel J, Capell H, et al. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial. Br J Clin Pharmacol 1983;15 Suppl 1:113S-116S.
91. Ettinger WH, Wise RA, Schaffhauser D, Wigley FM. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1984;77:451-456.
92. Coffman JD, Rasmussen HM. Effect of thromboxane synthetase inhibition in Raynaud's phenomenon. Clin Pharmocol Ther 1984;36:369-373.
93. Khan F, Litchfield SJ, McLaren M, Veale DJ, Littleford RC, Belch JJ. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arthritis Rheum 1997;40:352-357.
94. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335:1816-1828.
95. Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998;114: 561S-578S.
96. Clagett GP, Anderson FAJ, Geerts W, Heit JA, Knudson M, Lieberman JR, et al. Prevention of venous thromboembolism. Chest 1998;114:531S-560S.
97. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1:1309-1312.
98. Hull RD, Raskob GH, Hirsh J, Jay RM, Leclerc JR, Geerts WH, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315: 1109-1114.
99. Hull RD, Raskob GE, Brant RF, Pinco GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997;157:2562-2568.
100. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 1993;119:874-881.
101. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-1173.
102. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96:561-565.
103. Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud JM, Livio JJ, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 1983;309:954-958.
104. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
105. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152- 156.
106. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
107. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-809.
108. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995;155:601-607.
109. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br Med J 1994; 309:299-304.
110. Levine M, Gent M, Hirsh J, Ledere J, Anderson D, Weitz I, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681.
111. Koopman MM, Prandoni P, Piovella F, Ockelford PA, van Brandjes DP, et al, for the Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687.
112. Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin: an economic perspective. Arch Intern Med 1997;157:289-294.
113. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-858.
114. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681.
115. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907.
116. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al, for the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398.
117. Francis GW, Pellegrini VDJ, Marder VJ, Totterman S, Harris CM, Gabriel KR, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA 1992;267:2911-2915.
118. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347:635-639.
119. Kriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335.
120. de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism: a randomized controlled trial. Ann Intern Med 1995;123:1-9.
121. Goldhaber SZ, Meyerovitz MF, Green D, Vogelzang RL, Citrin P, Heit J, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990;88:235-240.
122. Goldhaber SZ, Polak JF, Feldstein ML, Meyerovitz MF, Creager MA. Efficacy and safety of repeated boluses of urokinase in the treatment of deep venous thrombosis. Am J Cardiol 1994;73:75-79.
123. Turpie AG, Levine MN, Hirsh J, Ginsberg JS, Cruickshank M, Jay R, et al. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis: results of a randomized trial. Chest 1990;97:172S-175S.